Souhaitez-vous accéder aux communiqués récents ?

Continued strategic refocusing in a challenging market environment Revenue of €892.4 million in 2025 (-5.4% vs. 2024 restated1)Adjusted EBITDA margin of 7.3% (-60 bp)Gross cash of €73.2 million and...

Sanuwave Announces Record Revenues and Financial Results for Q4 and Full Year 2025

Hyderabad, March 26, 2026 (GLOBE NEWSWIRE) -- According to Mordor Intelligence, the home healthcare market size was valued at USD 335.22 billion in 2025 and is projected to grow from USD 363.58...

RADNOR, Pa., March 24, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related...

Approval in moderate-to-severe patients was based on pivotal trial results showing over four times more Dupixent patients experienced sustained disease remission through Week 36 compared with placebo ...

Dupixent, développé par Sanofi et Regeneron, a été approuvé au Japon comme premier médicament ciblé pour le traitement des adultes atteints de pemphigoïde bulleuse L’approbation chez les patients...

Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid Approval in moderate-to-severe patients was based on pivotal study results...

SLINGERLANDS, N.Y., March 23, 2026 (GLOBE NEWSWIRE) -- Plug Power Inc. (NASDAQ: PLUG), a global leader in comprehensive hydrogen solutions for the hydrogen economy, today announced that members of...

Communiqué information réglementée Paris, le 19 mars 2026 Mise à disposition du document d’enregistrement universel 2025 et du rapport financier annuel du Groupe BPCE Le Groupe BPCE informe que le...

COURTOIS SASociété anonyme au capital de 1.673.940 EurosSiège social : 3, rue Mage BP 4853131685 TOULOUSE CEDEX 6540 802 105 RCS TOULOUSETel : 05.62.26.73.22Contact...